Hospital admissions (days)
| | | | | |
ICU/CCU | 3743 | 4210 | NS | −467 | −1541 to 607 |
Cardiology/medical ward | 7962 | 7452 | NS | 510 | −988 to 2008 |
Thoracic surgery ICU | 1927 | 1845 | NS | 82 | −676 to 840 |
Thoracic surgery ward | 1575 | 1612 | NS | −37 | −576 to 502 |
Other wards | 1584 | 1576 | NS | 8 | −723 to 739 |
All admissions
| 16791 | 16695 | NS | 96 | −2970 to 3162 |
| | | | | |
Investigations
| | | | | |
Exercise test | 862 | 909 | 0.03 | −47 | −93.6 to −0.4 |
Echocardiogram | 64 | 58 | NS | 6 | −21.6 to 33.6 |
Coronary catheterisations* | 1640 | 1852 | NS | −212 | −580 to 156 |
All investigations
| 2566 | 2819 | NS | −253 | −622 to 116 |
| | | | | |
Interventions
| | | | | |
PTCA without stent | 1158 | 1388 | NS | −230 | −920 to 460 |
PTCA with stent | 2224 | 2504 | NS | −280 | −1 205 to 645 |
CABG | 5950 | 6184 | NS | −234 | −2 232 to 1764 |
All interventions
| 9332 | 10076 | NS | −744 | −3 009 to 1521 |
| | | | | |
Pharmaceuticals
| | | | | |
Streptokinase | 3.6 | 9.0 | NS | −5.4 | −12.0 to 1.2 |
Alteplase | 45.4 | 117.0 | NS | −71.6 | −154.6 to 11.4 |
Reteplase | 9.1 | 9.0 | NS | 0.1 | −24.9 to 25.1 |
Abciximab | 56.0 | 46.0 | NS | 10.0 | −51.0 to 71.0 |
Intervention treatment
| | | | | |
Dalteparin (10 000 IU per day/placebo | 1753 | 0 | <0.001 | 1753 | 1587 to 1919 |
Dalteparin 15 000 IU per day/placebo | 6037 | 0 | <0.001 | 6037 | 5753 to 6321 |
All pharmaceuticals
| 7904 | 181 | <0.001 | 7723 | 7518 to 7928 |
| | | | | |
Outpatient care
| | | | | |
Visits to physician | 4451 | 4410 | NS | 41 | −120 to 202 |
Visits to nurse | 259 | 276 | NS | −17 | −63 to 29 |
Visit to physiotherapist | 194 | 213 | NS | −19 | −82 to 44 |
Physician home visits | 137 | 119 | NS | 17 | −53 to 87 |
Nurse home visits | 110 | 216 | NS | −106 | −274 to 62 |
All outpatient care
| 5151 | 5234 | NS | −83 | −350 to 184 |
| | | | | |
All costs
|
41744
|
35005
|
0.008
|
6739
|
1739 to 11739
|